Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Feb;104(2):256-65.
doi: 10.1111/j.1360-0443.2008.02455.x.

Buprenorphine tapering schedule and illicit opioid use

Walter Ling  1 , Maureen Hillhouse, Catherine Domier, Geetha Doraimani, Jeremy Hunter, Christie Thomas, Jessica Jenkins, Albert Hasson, Jeffrey Annon, Andrew Saxon, Jeffrey Selzer, Joshua Boverman, Richard Bilangi
Affiliations
Randomized Controlled Trial

Buprenorphine tapering schedule and illicit opioid use

Walter Ling et al. Addiction. 2009 Feb.

Abstract

Aims: To compare the effects of a short or long taper schedule after buprenorphine stabilization on participant outcomes as measured by opioid-free urine tests at the end of each taper period.

Design: This multi-site study sponsored by Clinical Trials Network (CTN, a branch of the US National Institute on Drug Abuse) was conducted from 2003 to 2005 to compare two taper conditions (7 days and 28 days). Data were collected at weekly clinic visits to the end of the taper periods, and at 1-month and 3-month post-taper follow-up visits.

Setting: Eleven out-patient treatment programs in 10 US cities.

Intervention: Non-blinded dosing with Suboxone during the 1-month stabilization phase included 3 weeks of flexible dosing as determined appropriate by the study physicians. A fixed dose was required for the final week before beginning the taper phase.

Measurements: The percentage of participants in each taper group providing urine samples free of illicit opioids at the end of the taper and at follow-up.

Findings: At the end of the taper, 44% of the 7-day taper group (n = 255) provided opioid-free urine specimens compared to 30% of the 28-day taper group (n = 261; P = 0.0007). There were no differences at the 1-month and 3-month follow-ups (7-day = 18% and 12%; 28-day = 18% and 13%, 1 month and 3 months, respectively).

Conclusion: For individuals terminating buprenorphine pharmacotherapy for opioid dependence, there appears to be no advantage in prolonging the duration of taper.

Trial registration: ClinicalTrials.gov NCT00078117.

PubMed Disclaimer

Conflict of interest statement

Declarations of interest

None.

Comment in

References

    1. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43:72–8. - PubMed
    1. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;27:2750–5. - PubMed
    1. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1025–30. - PubMed
    1. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401–7. - PubMed
    1. Ling W, Charuvastra C, Collins JF, Batki S, Brown LSJr, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93:475–86. - PubMed

Publication types

Associated data